Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking?

Journal of the American College of Cardiology

Volumn 30, Issue 7, 1997, Pages 1589-1597

  Uretsky, Barry F ^a,b   Sheahan, Richard G ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b John Sealy Hospital and John Sealy Annex   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIGOXIN; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; METOPROLOL; PLACEBO; TIMOLOL; TRANDOLAPRIL; VERAPAMIL; ZOFENOPRIL;

CARDIOVASCULAR DISEASE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; HEART FAILURE; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SUDDEN DEATH; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DIGOXIN; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; RISK FACTORS;

EID: 0031543303     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00361-6     Document Type: Review

References (89)

1. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
2. Effect of enalapril mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
3. Gradman A, Deedwania P, Cody R, Massie B, Pitt B, Goldstein S. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol. 14:1989;564-570.
4. Wilson JR, Schwartz JS, Sutton MSJ, et al. Prognosis in heart failure relation to hemodynamic measurements and ventricular ectopic activity . J Am Coll Cardiol. 2:1983;403-410.
5. Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol. 65:1990;421-481.
6. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 51:1983;831-836.
7. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study . N Engl J Med. 316:1987;1429-1435.
8. Califf RM, Adams K, Uretsky BF, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure the Flolan International Randomized Survival Trial (FIRST) . Am Heart J. 134:1997;44-54.
9. Reiter MJ. Effects of mechano-electrical feedback potential arrhythmogenic influence in patients with congestive heart failure . Cardiovasc Res. 32:1996;44-51.
10. Meissner MD, Akhtar M, Lehmann MH. Nonischemic sudden tachyarrhythmic death in atherosclerotic heart disease. Circulation. 84:1991;905-912.
11. Davies MJ. Anatomic features in victims of sudden coronary death coronary artery pathology . Circulation. 85:(Suppl I):1992;I-19-I-24.
12. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction . Circulation. 92:1995;1701-1709.
13. Luu M, Stevenson LW, Brunken RC, Drinkwater DC, Schelbert HR, Tillisch JH. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 80:1989;1675-1680.
14. Blanck Z, Akhtar M. Therapy of ventricular tachycardia in patients with nonischemic cardiomyopathies. J Cardiovasc Electrophysiol. 7:1996;671-683.
15. Mock MB, Ringqvist I, Fisher L, et al. Survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 66:1982;562-568.
16. Powell AC, Fuchs T, Finkelstein DM, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation. 88:1993;1083-1092.
17. Domanski MJ, Garg R, Yusuf S. Prognosis in congestive heart failure. Hosenpud JD, Greenberg BH. Congestive Heart Failure. 1994;622-627 Springer-Verlag, New York.
18. Birgersdotter-Green U, Rosenqvist M, Ryden L. Effect of congestive heart failure treatment on incidence and prognosis of ventricular tachyarrhythmias. J Cardiovasc Pharm. 17:(Suppl 6):1991;S53-S58.
19. Bigger JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 69:1984;250-258.
20. Hofmann T, Meinertz T, Kasper W, et al. Mode of death in idiopathic dilated cardiomyopathy a multivariate analysis of prognostic determinants . Am Heart J. 116:1988;1455-1461.
21. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction two-year follow-up . Am J Cardiol. 54:1984;31-36.
22. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
23. Doval HC, Nul DR, Grancelli HD, et al., for the GESICA-GEMA Investigators. Nonsustained ventricular tachycardia in heart failure: independent marker of increased mortality due to sudden death. Circulation 1996;94:3198-203.
24. Swedberg K, Eneroth P, Kjekshus J, Wilhelmson L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-6.
25. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure relations to survival and the effects of therapy in V-HeFT II . Circulation. 87:(Suppl VI):1993;VI-40-VI-48.
26. Gottlieb SS, Kukin M, Ahern D. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 13:1989;1534-1539.
27. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 73:1986;257-267.
28. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 83:1991;778-786.
29. Gomes JA, Winters SL, Stewart D, Horowitz S, Milner M, Barreca P. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction, based on signal-averaged electrocardiogram, radionuclide ejection fraction, and Holter monitoring. J Am Coll Cardiol. 10:1987;349-357.
30. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious antiarrhythmic events after myocardial infarction, based on signal-averaged electrocardiogram, radionuclide ejection fraction, and Holter monitoring. J Am Coll Cardiol. 9:1987;531-538.
31. Steinberg JS, Regan A, Sciacca RR, Bigger JM, Fleiss JL. Predicting arrhythmic events after acute myocardial infarction using the signal averaged electrocardiogram. Am J Cardiol. 69:1992;13-21.
32. Middlekauff HR, Stevenson WG, Woo MA, Moser DK, Stevenson LW. Comparison of frequency of late potentials in idiopathis dilated cardiomyopathy and ischemic cardiomyopathy with advanced congestive heart failure and their usefulness in predicting sudden death. Am J Cardiol. 66:1990;1113-1117.
33. Hurwitz JL, Josephson ME. Sudden cardiac death in patients with chronic coronary heart disease. Circulation. 85:(Suppl I):1992;I-43-I-49.
34. Keeling PJ, Kulakowski P, Yi G, Slade AKB, Bent SE, McKenna WJ. Usefulness of signal-averaged electrocardiogram in idiopathic dilated cardiomyopathy for identifying patients with ventricular arrhythmias. Am J Cardiol. 72:1993;78-84.
35. Stevenson WG, Stevenson LW, Weiss J, Tillisch JH. Inducible ventricular arrhythmias and sudden death during vasodilator therapy of advanced heart failure. Am Heart J. 124:1992;123-130.
36. Poll DS, Marchlinski FE, Buxton AF, Josephson ME. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. Am J Cardiol. 58:1986;992-997.
37. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ. Electrophysiological testing and nonsustained ventricular tachycardia use and limitations in patients with coronary artery disease and impaired ventricular function . Circulation. 82:1990;350-358.
38. Morady F, Scheinman MM, Hess DS, Sung RJ, Shen E, Shapiro W. Electrophysiologic testing in the management of survivors of out-of-hospital cardiac arrest. Am J Cardiol. 51:1983;85-89.
39. Daubert J, Higgins SL, Zareba W, Wilber DJ. Comparative survival of MADIT-eligible but noninducible patients [abstract]. J Am Coll Cardiol. 29:(Suppl A):1997;78A.
40. Podrid PJ, Fogel RI, Tordjman-Fuchs T. Arrhythmia in patients with a cardiomyopathy and congestive heart failure. In: Hosenpud JD, Greenberg BH, editors. New York: Springer-Verlag, 1994:645-86.
41. Moss AJ, Hall J, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 335:1996;1933-1940.
42. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 2:1993;821-827.
43. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 327:1992;669-677.
44. Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 332:1995;80-85.
45. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 333:1995;1670-1676.
46. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
47. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
48. Grinstead WC, Francis MJ, Marks GF, Tawa CB, Zoghbi WA, Young JB. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol. 73:1994;881-886.
49. Held P. Effects of beta blockers on ventricular dysfunction after myocardial infarction tolerability and survival effects . Am J Cardiol. 71:1993;39C-44C.
50. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;329:149-55.
51. A randomized trial of beta-blockade in heart failure. Circulation. 90:1994;1765-1773.
52. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
53. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II [DAVIT II]). Am J Cardiol. 66:1990;779-785.
54. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). Eur Heart J. 9:1988;354-364.
55. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 319:1988;385-392.
56. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
57. Echt DS, Liebson PR, Mitchell B, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo the Cardiac Arrhythmia Suppression Trial . N Engl J Med. 324:1991;781-788.
58. Effect of antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
59. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D, Jordi H. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias Basel Antiarrhythmic Study of Infarct Survival (BASIS) . J Am Coll Cardiol. 16:1990;1711-1718.
60. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction a double-blind, placebo-controlled, pilot study . J Am Coll Cardiol. 20:1992;1056-1062.
61. Navarro-Lopez F, Casin J, Marrugat J, et al. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Am J Cardiol. 72:1993;1243-1248.
62. Cairns JA, Roberts R, Gent M, for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82.
63. Julian DG, Camm AJ, Frangin J, et al. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-674.
64. Gottlieb SS. Dead is dead. Lancet. 349:1997;662-663.
65. Singh SN, Fletcher RD, Gross Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
66. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 344:1994;493-498.
67. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 348:1996;7-12.
68. Sweeney MO, Ruskin JN. Mortality benefits and the implantable cardioverter-defibrillator. Circulation. 89:1994;1851-1858.
69. Josephson M, Nisam S. Prospective trials of implantable cardioverter defibrillators drugs are they addressing the right question? Am J Cardiol. 77:1996;859-863.
70. Tchou PJ, Kadri N, Anderson J, Caceres JA, Jazayeri M, Akhtar M. Automatic implantable cardioverter defibrillator and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med. 109:1988;529-534.
71. Fogoros RN, Elson JJ, Bonnet CA, Fiedler SB, Chenarides JG. Long-term outcome of survivors of cardiac arrest whose therapy is guided by electrophysiologic testing. J Am Coll Cardiol. 19:1992;780-788.
72. Fazio G, Veltri EP, Tomaselli G, Lewis R, Griffith LSC, Guarnieri T. Long-term follow-up of patients with nonischemic dilated cardiomyopathy and ventricular tachyarrhythmias treated with implantable cardioverter defibrillators. PACE. 14:1991;1905-1910.
73. Newman D, Sauve MJ, Herre J, et al. Survival after implantation of the cardioverter defibrillator. Am J Cardiol. 69:1992;899-903.
74. Crandall BG, Morris CD, Cutler JE, et al. Implantable cardioverter-defibrillator therapy in survivors of out-of-hospital sudden cardiac death without inducible arrhythmias. J Am Coll Cardiol. 21:1993;1186-1192.
75. Sweeney MO, Ruskin JN, Garan H, et al. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation. 92:1995;3273-3281.
76. Zipes DP, Roberts D, for the Pacemaker Cardioverter-Defibrillator Investigators. Results of the international study of the implantable pacemaker cardioverter-defibrillator: a comparison of epicardial and endocardial lead systems. Circulation 1995;92:59-65.
77. Boyko W, Schulman KA, Tracy CM, Glick H, Solomon AJ. The economic impact of prophylactic defibrillators [abstract]. J Am Coll Cardiol. 29:(Suppl A):1997;256A.
78. Owens DK, Sanders GD, Harris RA, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 126:1997;1-12.
79. Goeree R, Manalich J, Grootcndorst P, Beecraft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med. 18:1995;455-464.
80. Goldman L. Cost and quality of life thrombolysis and primary angioplasty . J Am Coll Cardiol. 25:(Suppl):1995;385-415.
81. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 333:1995;267-273.
82. The cost-effectiveness of preventing initial coronary events with pravastatin results of the West of Scotland Coronary Prevention Study economic analysis [abstract] . J Am Coll Cardiol. 29:(Suppl A):1997;168A.
83. Prospective studies assessing prophylactic therapy in high risk patients the German Dilated Cardiomyopathy Study (GDCMS) - study design . PACE. 15:1992;697-700.
84. Cardiomyopathy trial. PACE. 16:1993;576-581.
85. Bardy GH, Lee KL, Mark DB. The Sudden Cardiac Death in Heart Failure Trial pilot study [abstract] . PACE. 20:1997;1148.
86. Moss AJ, Hall WJ. Implantable defibrillators in patients with coronary artery disease at high risk for ventricular arrhythmis. N Engl J Med. 336:1997;1677.
87. NHLBI Communications Office. NHLBI stops arrhythmia study - implantable cardiac defibrillators reduce death. Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute; 1997 Apr. NIH News Release.
88. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS) study design and organization . Am J Cardiol. 72:1993;103F-108F.
89. Siebels J, Kuck K-H. Implantable cardioverter-defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 127:1994;1139-1144.